There are a number of these medications currently available, some of which include: Semaglutide injection (Ozempic) Semaglutide injection (Wegovy) Semaglutide tablets (Rybelsus) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide extended-release (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Tirzepatide injection (Mounjaro) Source [1] Global GLP-1 receptor agonist market In 2024, the global GLP-1 receptor agonist market size was valued at an estimated USD 53.46 billion and is projected to reach USD 156.71 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 17.46% between 2025 and 2030
In the primary Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), retatrutide was studied across several dose levels, including: 1 mg (low dose) 4 mg (mid dose) 8 mg (higher dose) 12 mg (highest dose) These doses were administered as once-weekly subcutaneous injections
#Diabetes #ClinicalTrials #GLP1 #Orforglipron #Endocrinology #HealthcareInnovation #MedicalWriting #medicalaffairs To view or add a comment, sign in Explore content categories
But that figure is the market the innovators built: until 21 March, semaglutide was still on patent, so almost all of it was Novos and Lillys branded money
